Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Purchased by Vanguard Capital Wealth Advisors

Vanguard Capital Wealth Advisors increased its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 3.8% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,450 shares of the biotechnology company’s stock after purchasing an additional 90 shares during the period. Vanguard Capital Wealth Advisors’ holdings in Sarepta Therapeutics were worth $236,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of the stock. Handelsbanken Fonder AB raised its holdings in Sarepta Therapeutics by 14.5% in the 3rd quarter. Handelsbanken Fonder AB now owns 15,915 shares of the biotechnology company’s stock valued at $1,929,000 after acquiring an additional 2,013 shares during the last quarter. Harbor Capital Advisors Inc. raised its holdings in Sarepta Therapeutics by 6.4% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 3,244 shares of the biotechnology company’s stock valued at $393,000 after acquiring an additional 196 shares during the last quarter. DMC Group LLC raised its holdings in Sarepta Therapeutics by 2.9% in the 3rd quarter. DMC Group LLC now owns 3,297 shares of the biotechnology company’s stock valued at $400,000 after acquiring an additional 93 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in Sarepta Therapeutics by 5.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 95,865 shares of the biotechnology company’s stock valued at $11,621,000 after acquiring an additional 4,763 shares during the last quarter. Finally, TD Asset Management Inc raised its holdings in Sarepta Therapeutics by 377.7% in the 3rd quarter. TD Asset Management Inc now owns 204,626 shares of the biotechnology company’s stock valued at $24,805,000 after acquiring an additional 161,788 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. UBS Group increased their price objective on shares of Sarepta Therapeutics from $164.00 to $167.00 and gave the company a “buy” rating in a report on Friday, March 1st. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $128.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, February 29th. BMO Capital Markets began coverage on shares of Sarepta Therapeutics in a research report on Wednesday, January 31st. They set an “outperform” rating and a $170.00 price objective for the company. Needham & Company LLC lowered their price objective on shares of Sarepta Therapeutics from $169.00 to $166.00 and set a “buy” rating for the company in a research report on Thursday, February 29th. Finally, Mizuho increased their price objective on shares of Sarepta Therapeutics from $130.00 to $145.00 and gave the stock a “buy” rating in a research report on Wednesday, February 14th. Four analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $156.60.

Sarepta Therapeutics Stock Down 1.7 %

SRPT stock traded down $2.14 during midday trading on Tuesday, hitting $126.66. The company’s stock had a trading volume of 1,092,767 shares, compared to its average volume of 998,905. Sarepta Therapeutics, Inc. has a 52-week low of $55.25 and a 52-week high of $159.89. The firm has a 50-day simple moving average of $125.99 and a 200-day simple moving average of $110.36. The firm has a market capitalization of $11.97 billion, a P/E ratio of -20.70 and a beta of 0.94. The company has a quick ratio of 3.45, a current ratio of 3.95 and a debt-to-equity ratio of 1.32.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Wednesday, February 28th. The biotechnology company reported $0.47 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.50. Sarepta Therapeutics had a negative net margin of 43.11% and a negative return on equity of 18.97%. The business had revenue of $396.80 million for the quarter, compared to analyst estimates of $387.18 million. During the same period last year, the business earned ($1.24) EPS. The company’s revenue was up 53.6% on a year-over-year basis. As a group, equities analysts forecast that Sarepta Therapeutics, Inc. will post 2.13 EPS for the current year.

Insider Activity

In related news, Director Kathryn Jean Boor sold 761 shares of Sarepta Therapeutics stock in a transaction on Monday, March 11th. The shares were sold at an average price of $122.93, for a total transaction of $93,549.73. Following the sale, the director now directly owns 7,516 shares in the company, valued at approximately $923,941.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Kathryn Jean Boor sold 761 shares of Sarepta Therapeutics stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $122.93, for a total value of $93,549.73. Following the sale, the director now owns 7,516 shares of the company’s stock, valued at $923,941.88. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Hans Lennart Rudolf Wigzell sold 15,000 shares of Sarepta Therapeutics stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $123.25, for a total transaction of $1,848,750.00. Following the transaction, the director now owns 22,840 shares of the company’s stock, valued at approximately $2,815,030. The disclosure for this sale can be found here. In the last three months, insiders have sold 22,096 shares of company stock worth $2,739,419. 7.40% of the stock is currently owned by corporate insiders.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.